Over the next five years, Anna Obenauf’s research on cancer metastasis and therapy resistance will be supported with ~1.5 million Euro through a Starting Grant of the European Research Council (ERC). This is the 41st of the prestigious ERC research grants that is awarded to a VBC scientist since 2007.
The Vienna BioCenter accounts for approximately half of all ERC awards in Austria and is a main player for life-sciences research in Europe.
In total, the institutes at the Vienna BioCenter have hosted an impressive 41 ERC grants over the last 10 years: 23 Starting Grants, 5 Consolidator Grants, 12 Advanced Grants and 1 Proof of Concept. These grants have brought over 70 million EUR of funding.
In her ERC-funded research project “CombaTCancer”, Anna Obenauf -Group Leader at IMP- and her team will investigate how tumors resist current cancer therapies. The focus of this project is on the evolution of the cancer cells during the treatment and the tumor microenvironment, which has a strong impact on cancer progression and therapy responses. Ultimately, her goal is to identify more powerful treatment combinations, that result in durable responses of cancer patients.
“We are really excited about a novel method we are developing, which will allow us to get unprecedented insights into the evolution of cancer cells during therapy” says Anna Obenauf.
About the ERC funding scheme
The European Research Council (ERC) grant scheme was established in 2007. “Starting Grants” award up to 1.5 million Euro for a period of 5 years to talented early-career scientists who have demonstrated a potential to develop into leaders in their fields of research. Due to the rigorous evaluation underlying this award, the ERC grants can serve as indicators of academic excellence. Anna Obenauf’s Starting Grant is the 16th ERC grant given to an IMP scientist. Of the currently 16 IMP faculty members, 11 are “ERC grantees”.
About Anna Obenauf
Anna Obenauf joined the IMP at Vienna BioCenter as a group leader in December 2015. Her lab studies the molecular mechanisms of metastasis and drug resistance. Prior to starting her own lab, Anna Obenauf was a postdoctoral researcher at the Memorial Sloan Kettering Cancer Center in New York for five years. She did her PhD at the Medical University of Graz.
Photo: © IMP/Obenauf